%PDF-1.3
%
6 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
7 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
3 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
9 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
1 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
5 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
8 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
4 0 obj
<>>>/BBox[0 0 612 792]/Length 53>>stream
xs
w3T0WI2P0T5T R
Ɩf
!\!Y\ !p
o
endstream
endobj
11 0 obj
<>stream
2021-02-25T06:28:31+05:30
Arbortext Advanced Print Publisher 9.0.114/W
2021-04-23T01:41:05-07:00
Acrobat Distiller 8.1.0 (Windows); modified using iText 4.2.0 by 1T3XT
application/pdf
CAP-2020-0123-ver9-Oerbeck_2P 1..8
uuid:c5d482b8-0515-4f7d-a307-b893101aa582
uuid:7635df4b-d0ae-459a-95e8-f3e65087af98
endstream
endobj
12 0 obj
<>stream
x+ |
endstream
endobj
13 0 obj
<>stream
xS**T0T0 Bi ye(
endstream
endobj
14 0 obj
<>stream
x+ |
endstream
endobj
15 0 obj
<>stream
xS**T0T0 Bi yJ%
endstream
endobj
16 0 obj
<>stream
x+ |
endstream
endobj
17 0 obj
<>stream
xS**T0T0 Bi y8#
endstream
endobj
18 0 obj
<>stream
x+ |
endstream
endobj
19 0 obj
<>stream
xS**T0T0 Bi yw*
endstream
endobj
20 0 obj
<>stream
x+ |
endstream
endobj
21 0 obj
<>stream
xS**T0T0 Bi yA$
endstream
endobj
22 0 obj
<>stream
x+ |
endstream
endobj
23 0 obj
<>stream
xS**T0T0 Bi yn)
endstream
endobj
24 0 obj
<>stream
x+ |
endstream
endobj
25 0 obj
<>stream
xS**T0T0 Bi y\'
endstream
endobj
26 0 obj
<>stream
x+ |
endstream
endobj
27 0 obj
<>stream
xS**T0T0 Bi yS&
endstream
endobj
29 0 obj
<>stream
/GS1 gs
BT
/F5 1 Tf
8.9663 0 0 8.9663 72 725.7825 Tm
0 0 0 rg
0 Tc
0 Tw
[(As)-534.6(many)-535.1(major)-541.3(psychiatric)-536.2(disorders)-540.8(have)-540.3(an)-532.6(onset)-536.3(before)]TJ
-1.1128 -1.2203 TD
[(age)-395.4(18,)-394(medication)-403.7(has)-394.2(been)-394.9(increasingly)-396.6(utilized)-402.7(in)-395.1(youth,)-390.2(but,)]TJ
0 -1.2266 TD
[(as)-401(pointed)-405.4(out)-400.9(in)-401.4(an)-406.1(important)-401.9(review)-403.9(about)-402.3(10)-403.7(years)-404.5(ago,)-402.2(psy-)]TJ
0 -1.2203 TD
[(chopharmacologic)-612.8(treatments)-603.5(in)-610(pediatric)-605.6(patients)-608.5(also)-606.3(raised)]TJ
T*
[(concerns)-475(regarding)-471.2(a)-476.1(potential)-471.8(overtreatment,)-476(without)-473.5(adequate)]TJ
0 -1.2266 TD
[(data)-424.2(regarding)-420.7(the)-422.3(pediatric)-428.5(efcacy)-424.8(and)-418.3(safety)-427(of)-418.9(psychotropic)]TJ
0 -1.2203 TD
[(classes)-365.5(\(Correll)-360.5(et)-359.5(al.)-362.5(2011\).)-357.2(The)-361.2(authors)-360.9(still)-362.6(concluded)-361(that)-362.6(for)]TJ
T*
[(three)-356.8(frequently)-361(used)-355.7(classes,)-362.1(that)-356.3(is,)-354.9(stimulants,)-363.9(antidepressants,)]TJ
0 -1.2266 TD
[(and)-424.6(antipsychotics:)-427.1()54.8(effect)-426.7(sizes)-426.1(against)-428(placebo)-425.2(have)-426.5(typically)]TJ
0 -1.2203 TD
[(been)-413.9(at)-416.5(least)-416.3(moderate,)-414.8(with)-414.1(most)-411.5(numbers-needed-to-treat)-418.8(well)]TJ
T*
[(below)-279.2(10)-283.6(for)-282(response,)-280.7(indicating)-281.6(clinical)-285(signicance)-284(as)-280.8(well.)52.7()]TJ
1.1128 -1.2203 TD
[(In)-260.9(a)-273.8(m)0(o)22.7(r)0(e)-263.3(r)0(e)14.9(c)0(e)21.4(n)0(t)-262.3(r)0(e)21.2(v)0(i)15.9(e)0(w)20.5(,)-274.8(st)21.1(im)18.7(u)13.1(l)0(a)19.8(n)0(t)15.9(s)0(,)-262.9(s)0(e)22.7(l)0(e)19.8(c)0(t)13.5(i)15.4(ve)-267(se)22.7(ro)17.3(to)22.2(ni)15.9(n)-271.4(r)0(e)21.2(u)0(p)19.9(t)0(a)19.8(k)0(e)]TJ
-1.1128 -1.2266 TD
[(in)22.2(hi)15.9(b)13.1(i)0(t)18.2(o)0(r)17.3(s)-430.7(\(S)18.8(SR)23(Is)16.2(\),)-422.3(an)17.5(d)-429.5(a)0(n)17.5(t)15.4(ip)15.9(sy)18.8(ch)23.9(ot)15.9(ic)19.8(s)-430.7(w)0(e)20.5(r)0(e)-427.7(f)0(o)23.7(u)0(n)19.9(d)-435.8(to)-420.4(h)13.1(a)0(v)17.5(e)-431.9(do)19.9(cu)17.5(-)]TJ
0 -1.2203 TD
[(me)20.3(nt)15.9(ed)-165.8(ef)14.9()14.6(c)0(a)15.1(c)0(y)-172.2(f)0(o)23.7(r)-179.2(at)13.5(t)15.4(e)0(n)17.5(t)0(i)18.2(o)13.1(n-)17.3(de)17.5(c)18.9(it)18.2(/)15.4(h)0(y)19.9(p)0(e)17.5(r)0(a)14.9(c)0(t)19.8(i)0(v)22.2(i)0(t)18.2(y)-176.6(di)15.9(so)18.8(rd)23.7(er)-174.8(\(A)20.4(DH)19.7(D\))20.4(,)]TJ
T*
[(pediatric)-377.9(depression/anxiety)-376(disorders,)-373(and)-374(childhood-onset)-373.8(schi-)]TJ
0 -1.2266 TD
[(zophrenia,)-278(respectively)-285.2(\(Giles)-273.9(and)-279.2(Martini)-279.9(2016\).)-275(The)-279(review)-277.4(also)]TJ
0 -1.2203 TD
[(reported)-459.1(that)-457.4(the)-460.2(evidence)-458.7(base)-453(for)-459(providing)-455.2(antipsychotics)-461.5(to)]TJ
T*
[(youth)-191.3(with)-192.8(bipolar)-199.3(mania)-193.3(and)-190.6(autism)-195.6(spectrum)-195.6(disorders)-193(\(ASD\))-197.6(had)]TJ
0 -1.2266 TD
[(grown,)-297.2(and)-298.1(that)-299.4(atypical)-299.9(antipsychotics)-297.1(were)-299.6(used)-298.8(in)-300.2(the)-295.8(pediatric)]TJ
0 -1.2203 TD
[(population)-483.8(for)-484.3(the)-485.5(management)-483.8(of)-482.2(aggressive)-485.6(and)-487.8(oppositional)]TJ
T*
[(behaviors,)-371.6(although)-367(there)-369.4(were)-375.5(concerns)-367.5(regarding)-370.1(adverse)-374.4(reac-)]TJ
T*
[(tions.)-338.5(Further,)-344.8(a)-337(study)-344.2(of)-336.7(dosage)-344.5(and)-336.1(prevalence)-342.6(of)-343.1(antipsychotic)]TJ
0 -1.2266 TD
[(prescriptions)-416.5(in)-414(Scandinavia)-421.9(from)-417.8(2006)-409(to)-420.4(2016)-409(found)-417.5(a)-412.9(steady)]TJ
0 -1.2203 TD
[(trend)-310.1(of)-305.1(low)-303(or)-305.1(decreasing)-309.8(dosages)-307.3(for)-307.2(the)-308.5(majority)-307.6(of)-305.1(commonly)]TJ
T*
[(used)-387.3(antipsychotics,)-388.5(suggesting)-387.3(that)-381.6(these)-387(are)-385.3(prescribed)-392.2(outside)]TJ
0 -1.2266 TD
[(their)-269.9(main)-273.6(indications)-269.7(\(e.g.,)-271.6(as)-268.2(anxiolytics,)-272.6(hypnotics)-266.5(or)-267.2(sedatives\))]TJ
0 -1.2203 TD
[(\(Hojlund)-281.9(et)-283.7(al.)-280.3(2019\).)]TJ
1.1128 -1.2203 TD
-.0146 Tc
[(Th)4.9(e)-307.4(u)-1.5(s)3.7(e)-307.4(o)4.9(f)-307.6(ps)3.7(ychotropic)-301.1(m)1.3(e)-14.6(d)9.3(ica)-14.6(t)11.6(io)4.9(n)-305(h)-1.5(as)-306.1(bee)-14.6(n)-294.2(fou)4.9(n)-1.5(d)-305(t).8(o)-305(v)4.9(a)-14.6(r)13(y)-305(c)2.4(on-)]TJ
-1.1128 -1.2266 TD
0 Tc
[(si)27.4(d)19.5(e)0(r)27.6(a)0(b)30.2(l)0(y)-350.8(b)13.1(e)17(t)15.4(we)26.9(en)-349.2(co)30.2(u)13.1(n)13.1(t)15.4(r)16.9(i)15.4(es)29(,)-363.3(a)0(s)-350.4(a)0(l)26.2(s)18.3(o)-366.2(c)17(o)13.1(n)13.1()14.6(r)16.9(m)15.9(ed)-349.2(i)15.4(n)-366.2(t)15.4(h)13.1(e)-362.3(r)16.9(ec)27.8(en)30.2(t)-363.9(i)15.4(n)13.1(t)15.4(er)27.6(-)]TJ
0 -1.2203 TD
-.0147 Tc
[(national)-201.6(r)2.2(evie)-14.7(w)12.2(,)-194.7(w)-14.7(h)14.6(e)-14.7(r)12.9(e)-200(U)1.5(.S.)-194.7(youth)-197.6(c)2.3(on)4.8(s)-14.7(i)12.7(s)-14.7(t)12.7(ently)-197.6(we)-14.7(r)12.9(e)-200(fou)4.8(n)-1.6(d)-197.6(a)-14.7(m)11.9(o)4.8(ng)-197.6(the)]TJ
T*
-.0143 Tc
[(high)-279.4(us)4(e)-14.3(r)13.3(s)-286.9(\()2.6(Piov)5.2(a)-14.3(n)9.6(i)-277.1(e)-14.3(t)-272.7(a)2.7(l.)-282.8(2019)5.2(\))-14.3(.)-272.2(T)5.3(h)-1.2(e)-281.8(r)-14.3(e)13.3(v)-1.2(iew)-289(r)2.6(eporte)-14.3(d)-268.7(t)1.1(hat)-283.4(t)1.1(he)-281.8(global)]TJ
0 -1.2266 TD
-.0149 Tc
[(ra)-14.9(n)9(d)4.6(om-e)-14.9(f)12.7(f)-14.9(e)12.7(c)-14.9(t)-279.6(poo)4.6(le)-14.9(d)-281.9(p)-1.8(reva)-14.9(l)11.3(e)2.1(nce)-295(o)-1.8(f)-295.2(p)4.6(s)-14.9(y)10.2(chotrop)4.6(i)-14.9(c)-279.6(d)-1.8(rug)-292.6(p)-1.8(re)-14.9(s)14.1(c)-14.9(r)12.7(i).5(ptions)]TJ
0 -1.2203 TD
0 Tc
[(am)26.6(o)19.5(n)13.1(g)-492.7(y)13.1(o)13.1(u)19.5(t)15.4(h)-492.7(wa)26.9(s)-493.9(1)13.1(5)19.5(.)0(3)]TJ
/F9 1 Tf
9.5792 0 TD
(&)Tj
/F5 1 Tf
1.4922 0 TD
-.0143 Tc
[(\()-14.3(9)15.7(5%)-509.1(con)6.6(de)-14.3(n)15.9(c)-14.3(e)-498.7(i)1.1(n)5.2(t)1.1(e)-14.3(r)13.3(val)-511([)2.6(CI)-14.3(])-492.7(7)-1.2(.6)]TJ
/F9 1 Tf
14.1127 0 TD
0 Tc
(&)Tj
/F5 1 Tf
.9864 0 TD
()Tj
-26.1705 -1.2203 TD
-.0131 Tc
[(25)6.4(.)-13.1(7)]TJ
/F9 1 Tf
1.6882 0 TD
0 Tc
(&)Tj
/F5 1 Tf
.9864 0 TD
-.0147 Tc
[(\))-282.4(f)2.2(or)-276.1(AD)-14.7(H)11.3(D)-276.7(m)-14.7(e)11.9(dica)-14.7(t)11.5(i).7(on)4.8(s)-14.7(,)-264.9(6.4)]TJ
/F9 1 Tf
11.5014 0 TD
0 Tc
(&)Tj
/F5 1 Tf
1.2646 0 TD
-.0147 Tc
[(\(95)4.8(%)-281.9(CI)-282.4(4)4.8(.)1.4(38.7)4.8(\))-282.4(for)-276.1(a)-14.7(n)9.2(tid)4.8(e)-14.7(-)]TJ
-15.4405 -1.2203 TD
0 Tc
[(p)13.1(r)16.9(es)29(sa)29(n)13.1(t)15.4(s,)-205.9(a)17(n)13.1(d)-214.5(5)13.1(.)16.1(5)]TJ
/F9 1 Tf
6.8414 0 TD
(&)Tj
/F5 1 Tf
1.214 0 TD
-.0144 Tc
[(\()-14.4(9)15.6(5%)-231(CI)-237.8(3)5.1(.)1.7(67.8)5.1(\))-237.8(for)-231.5(a)2.6(ntips)3.9(y)-1.3(c)-14.4(h)15.8(otic)-14.4(s)14.6(.)-232.3(Sys)3.9(t)-14.4(e)11.8(m)1.5(a)-14.4(t)11.8(ic)]TJ
-8.0554 -1.2266 TD
-.0156 Tc
[(monitoring)-198.5(wa)-15.6(s)-188.9(f)-15.6(o)14.4(und)-198.5(to)-204.8(be)-200.9(lac)-15.6(k)8.3(ing)-204.8(i)-.2(n)-204.8(m).3(os)-15.6(t)-190.5(c)1.4(ount)-15.6(r)10.4(ies)-15.6(,)-189.9(and)-204.8(t)-.2(he)-207.2(author)-15.6(s)]TJ
0 -1.2203 TD
0 Tc
[(n)13.1(o)19.5(te)26.2(d)-265.1(t)15.4(h)13.1(a)17(t)-269.1(p)19.5(re)27.6(v)13.1(a)17(l)15.4(e)0(n)23.9(c)17(e)-267.5(d)19.5(at)26.2(a)-267.5(b)19.5(y)-265.1(g)13.1(en)30.2(d)13.1(e)17(r)-267.7(w)16.2(er)27.6(e)-267.5(o)13.1(f)16.9(t)15.4(e)17(n)-265.1(mi)25(s)18.3(s)0(i)27.4(n)13.1(g)19.5(.)]TJ
1.1128 -1.2203 TD
[(In)-381(a)-387.6(study)-382.1(of)-387.3(U.S.)-386.1(national)-386(annual)-385.3(prescribing)-387(patterns)-385.8(of)-381(the)]TJ
-1.1128 -1.2266 TD
[(same)-399.6(three)-401(psychotropic)-402.8(classes,)-400(data)-405.2(from)-398.8(different)-402(age)-401.7(groups)]TJ
0 -1.2203 TD
[(were)-350.2(analyzed)-344.9(from)-341.9(a)-349.7(national)-348.1(longitudinal)-345.5(prescription)-346.2(database)]TJ
T*
(\()Tj
/F10 1 Tf
.3351 0 TD
(n)Tj
/F6 1 Tf
.6639 0 TD
(=)Tj
/F5 1 Tf
.7208 0 TD
[(6,351,482\))-244.8(\(Sultan)-248.5(et)-245.7(al.)-248.6(2018\).)-243.4(The)-247.4(total)-246(annual)-246.2(percentage)-254.1(of)]TJ
-1.7198 -1.2266 TD
[(prescriptions)-378.5(lled)-379.7(by)-372.1(youth)-374.6(for)-376.8(any)-374(of)-381(the)-371.7(three)-382.1(classes)-378.1(was)-372.2(by)]TJ
0 -1.2203 TD
[(age)-199.4(35)-194.5(years:)-193.1(0.8%,)-196.2(612)-194.1(years:)-199.4(5.4%,)-189.9(1318)-193.6(years:)-199.4(7.7%,)-196.2(and)-190.6(19)]TJ
T*
[(24)-302.5(years:)-300.6(6.0%.)-303.7(Stimulant)-300.8(use)-299.3(was)-302.6(highest)-299.1(for)-300.9(older)-303.8(children)-302.4(\(age)]TJ
T*
(11)Tj
/F6 1 Tf
1.1697 0 TD
(=)Tj
/F5 1 Tf
.7145 0 TD
[(5.7%\).)-425.9(Antidepressant)-431.8(use)-425.8(tended)-423.2(to)-426.7(increase)-430.9(with)-426.7(age)-427(and)]TJ
-1.8842 -1.2266 TD
[(was)-283.7(highest)-286.4(for)-282(young)-282.1(adults)-280.6(\(age)-283.7(24)]TJ
/F6 1 Tf
15.0928 0 TD
(=)Tj
/F5 1 Tf
.7208 0 TD
[(4.8%\).)-280.5(Annual)-285(antipsycho-)]TJ
-15.8136 -1.2203 TD
[(tic)-514.8(prescription)-516.9(percentages)-520.4(were)-514.6(lower)-515.7(than)-516.6(antidepressant)-519.4(or)]TJ
T*
[(stimulant)-385.6(percentages)-393.9(for)-383.1(all)-388.4(age)-382.7(groups,)-383.2(with)-388.8(a)-387.6(peak)-382.3(in)-388.7(adoles-)]TJ
0 -1.2267 TD
[(cence)-430.9(\(age)-429.1(16)]TJ
/F6 1 Tf
6.0447 0 TD
(=)Tj
/F5 1 Tf
.7145 0 TD
[(1.3%\).)-432.2(Annual)-424.1(stimulant)-429.8(and)-430.9(antipsychotic)-429.2(per-)]TJ
-6.7592 -1.2203 TD
[(centages)-232.3(for)-231.4(males)-226.1(were)-236.4(higher)-227.4(than)-225.8(corresponding)-236.5(percentages)-229.5(for)]TJ
T*
[(females,)-283.7(but)-280.8(they)-282.7(converged)-277.3(for)-282(young)-282.1(adults.)]TJ
1.1128 -1.2266 TD
[(Within)-504.2(the)-510.8(child)-507.5(welfare)-509.6(system,)-505.5(there)-508.5(is)-503.7(still)-508(a)-507.8(paucity)-509(of)]TJ
-1.1128 -1.2203 TD
[(studies)-414.1(on)-410(psychotropic)-415.5(medication)-416.3(use,)-409.7(and)-418.3(systematic)-412.4(data)-411.6(on)]TJ
T*
[(patterns)-347.9(of)-343.1(medication)-346.8(treatment,)-346.4(with)-344.5(a)-349.7(particular)-348.4(weight)-345.9(on)-340.5(the)]TJ
0 -1.2266 TD
[(use)-489(of)-488.5(concomitant)-485.4(drugs)-488.2(has)-489(been)-489.7(called)-486.6(for)-490.6(in)-483.6(the)-491.8(literature)]TJ
0 -1.2203 TD
[(\(Raghavan)-414.9(et)-403.8(al.)-413(2005;)-406.2(Zito)-410.6(et)-410.1(al.)-406.7(2008b\).)-413.6(In)-406.3(the)-409.6(following,)-408.5(we)]TJ
T*
[(therefore)-286.6(include)-281.3(relevant)-279.6(literature)-282.9(from)-285(the)-276.9(last)-281.6(two)-284.1(decades.)]TJ
1.1128 -1.2203 TD
[(An)-217.3(early)-224(report)-223.7(on)-220.3(Medicaid-enrolled)-228.1(youth)-222.9(in)-218(foster-care)-228.6(raised)]TJ
-1.1128 -1.2266 TD
[(concern)-354.2(as)-350.4(30%)-348.4(had)-348.7(received)-353.8(psychotropic)-345.9(medications)-353.8(\(dosReis)]TJ
0 -1.2203 TD
[(et)-321.6(al.)-324.5(2001\).)-319.2(Following)-319.4(up)-321.5(with)-319.2(a)-324.4(later)-322.9(study,)-321.8(the)-321.1(most)-316.6(frequently)]TJ
T*
[(used)-191.3(medications)-189.4(were)-192.2(antidepressants)-191.3(\(57%\),)-191.2(ADHD)-188.3(drugs)-191(\(56%\),)]TJ
0 -1.2267 TD
[(and)-355(antipsychotics)-360.3(\(53%\))-352.6(\(Zito)-355.8(et)-359.5(al.)-356.1(2008b\))-353.8(with)-350.8(frequent)-357.9(poly-)]TJ
27.9978 74.5598 TD
[(pharmacy,)-341.2(as)-337.7(41%)-335.8(of)-336.7(the)-333.8(youth)-336.7(in)-338.2(foster)-332.4(care)-343(received)]TJ
/F6 1 Tf
22.7182 0 TD
()Tj
/F5 1 Tf
.5564 0 TD
[(3)-334.6(differ-)]TJ
-23.2746 -1.2203 TD
[(ent)-365.4(classes)-359.2(of)-362(psychotropics,)-362.2(and)-361.4(the)-359.1(authors)-360.9(were)-362.9(concerned,)-358.6(as)]TJ
0 -1.2266 TD
[(polypharmacy)-213.9(increases)-216.6(the)-213.6(risk)-214.5(for)-212.4(adverse)-210(reactions)-217(\(Bogler)-209(et)-214.1(al.)]TJ
0 -1.2203 TD
[(2019\).)-205.4(Later)-211.2(studies)-205.4(have)-211.5(corroborated)-202.9(the)-207.3(high)-204.4(prevalence)-209.8(of)-210.3(poly-)]TJ
T*
[(pharmacy)-319.3(and)-317.1(demonstrated)-320.3(subgroup)-309.7(differences,)-323.7(such)-311.5(as)-318.8(higher)]TJ
0 -1.2266 TD
[(polypharmacy)-372(in)-369.8(boys)-372.3(compared)-369.9(with)-369.8(girls,)-366.4(and)-367.7(in)-369.8(group)-373.2(homes)]TJ
0 -1.2203 TD
[(compared)-287.7(with)-281.3(foster)-281.8(homes)-276.6(\(Keast)-284.9(et)-283.7(al.)-280.3(2019\).)]TJ
1.1128 -1.2203 TD
[(Although)-431.1(it)-424.4(is)-427.9(difcult)-429.1(to)-426.7(accurately)-428.8(compare)-433.6(the)-422.3(prevalence)]TJ
-1.1128 -1.2266 TD
[(of)-286.2(psychotropic)-282.7(medications)-290.6(due)-285.5(to)-281.3(different)-281.9(jurisdictions)-286.7(and)-285.5(dif-)]TJ
0 -1.2203 TD
[(ferent)-188.2(years)-183.2(and)-184.3(age)-186.7(groups)-184.2(reported)-180.9(in)-186.4(the)-182(literature,)-184.7(the)-182(prevalence)]TJ
T*
[(rates)-364.3(for)-351.5(the)-359.1(use)-356.2(of)-355.7(at)-359.6(least)-359.4(one)-355(psychotropic)-358.6(agent)-360.5(in)-357.1(U.S.)-354.5(child)]TJ
T*
[(welfare)-212.4(has)-210.8(been)-205.2(found)-208.8(to)-205.4(be)-210.1(as)-211.3(high)-204.4(as)-211.3(37%)-203(in)-211.7(older)-202.6(youth)-210.2(in)-205.4(foster)]TJ
0 -1.2266 TD
[(care)-286.1(\()-84.3(McMillen)-286.3(et)-283.7(al.)-286.6(2004\),)-281.3(and)-285.5(even)-287.4(used)-279.9(by)-283.6(the)-289.5(majority)-282.3(of)-286.2(the)]TJ
0 -1.2203 TD
[(study)-192.5(participants)-198.3(in)-186.4(therapeutic)-196(foster)-193.3(care)-191.3(\(67%\))-188.3(and)-197(group)-189.8(homes)]TJ
T*
[(\(77%\))-283.1(\(Breland-Noble)-283.5(et)-283.7(al.)-280.3(2004\).)]TJ
1.1128 -1.2266 TD
[(A)-571.9(recent)-573.7(review)-574.6(on)-568.1(psychotropic)-573.6(medications)-575.1(for)-572.8(different)]TJ
-1.1128 -1.2203 TD
[(groups)-196.9(of)-197.6(highly)-194.8(vulnerable)-202.7(children)-194.9(in)-199.1(the)-194.7(United)-200.5(States)-199.4(concluded)]TJ
T*
[(that)-432.1(they)-428.1(generally)-424.5(receive)-430.2(numerous)-429.5(psychotropic)-428.1(medications.)]TJ
0 -1.2266 TD
[(This)-275(includes)-275.7(high)-267.6(rates)-275.8(of)-273.5(polypharmacy,)-273.7(off-label)-269.2(use,)-276.9(and)-272.8(long-)]TJ
0 -1.2203 TD
[(term)-364.7(use,)-359.1(typically)-358(in)-357.1(the)-359.1(absence)-361.5(of)-362(adjunctive)-355.9(psychosocial)-365.9(in-)]TJ
T*
[(terventions)-413.7(\()-78(McLaren)-411.6(et)-403.8(al.)-406.7(2018\).)-407.8(The)-405.4(authors)-411.5(further)-402.9(reported)]TJ
T*
[(medication)-239.3(use)-236.1(among)-231.1(76%91%)-234.8(of)-235.6(the)-232.6(children)-239.2(within)-233.7(residential)]TJ
0 -1.2266 TD
[(treatment)-552.2(facilities,)-547.7(compared)-546.9(with)-540.5(7.5%)-547.3(in)-540.5(the)-542.4(general)-547.9(child)]TJ
0 -1.2203 TD
[(population,)-284.4(and)-279.2(13%40%)-279(in)-281.3(children)-283.5(placed)-280.2(in)-281.3(foster)-281.8(care.)]TJ
1.1128 -1.2203 TD
[(In)-368.4(a)-368.7(literature)-371.4(search)-374.8(on)-365.8(psychotropic)-371.2(medication)-365.7(use)-368.9(in)-369.8(child)]TJ
-1.1128 -1.2266 TD
[(welfare,)-537.8(the)-529.8(retrieved)-528.3(studies)-534.2(were)-533.6(generally)-532(from)-525.3(the)-529.8(United)]TJ
0 -1.2203 TD
[(States,)-284.5(as)-274.5(presented)-282.6(earlier,)-279.2(and)-279.2(none)-278.7(were)-280.7(from)-272.4(developing)-279.9(coun-)]TJ
T*
[(tries.)-311.9(We)-313.2(found)-310(only)-311.9(one)-310.8(Scandinavian)-307.6(study,)-309.2(showing)-314.9(that)-305.7(about)]TJ
0 -1.2266 TD
[(one-third)-207.3(of)-204(youth)-203.9(institutionalized)-209.3(for)-206.1(serious)-210.3(behavioral)-202.7(problems)]TJ
0 -1.2203 TD
[(in)-502.6(two)-505.4(Swedish)-505.6(adolescent)-507.2(units)-500(were)-502(given)-503.5(psychopharmaco-)]TJ
T*
[(logical)-405.5(treatment)-400.4(\(Anckarsa)]TJ
11.0714 .019 TD
()Tj
.3857 -.019 TD
[(ter)-399.6(et)-397.5(al.)-400.4(2007\).)-395.1(This)-401.4(lack)-398.9(of)-400(studies)]TJ
-11.4571 -1.2266 TD
[(is)-396.3(unfortunate)-398.4(as)-394.6(Scandinavian)-402.5(countries)-398(have)-394.9(prescription)-396.8(data-)]TJ
0 -1.2203 TD
[(bases)-339.9(available)-339.8(for)-332.5(all)-331.5(citizens,)-342(providing)-328.7(opportunities)-338.4(to)-331.8(inform)]TJ
T*
[(on)-283.6(representative)-283(populations.)]TJ
1.1128 -1.2203 TD
[(To)-169.6(th)15.9(e)-179(b)0(e)17.5(s)0(t)-168.6(o)0(f)-172.3(o)0(u)19.9(r)-179.2(kn)20(ow)16.6(le)19.8(dg)19.9(e,)-169.2(re)14.9(p)13.1(r)0(e)14.9(s)0(e)22.7(n)0(t)15.9(a)0(t)19.8(i)0(v)22.3(e)-185.3(S)14.6(c)0(a)15.1(n)13.1(di)15.9(n)13.1(a)0(v)17.5(i)0(a)19.8(n)-182.9(st)21.1(u)13.1(d)0(i)15.9(e)0(s)]TJ
-1.1128 -1.2266 TD
[(of)-197.6(th)22.2(e)-204.3(u)0(s)18.8(e)-204.3(of)-197.6(an)17.5(ti)24.5(de)17.5(pr)17.3(es)22.7(sa)16.3(n)13.1(t)0(s)14.7(,)-205.3(an)23.8(ti)18.2(ps)18.8(y)13.1(c)0(h)17.5(o)0(t)15.9(i)15.4(cs)16.3(,)-205.3(a)0(n)17.5(d)-201.8(st)21.1(im)18.7(u)13.1(l)0(a)13.5(n)13.1(ts)-193.9(ha)17.5(v)13.1(e)-210.6(n)13.1(o)0(t)]TJ
0 -1.2203 TD
[(be)17.5(en)-197.4(in)15.9(v)13.1(e)0(s)16.3(t)0(i)18.2(g)13.1(at)19.8(ed)-197.5(in)-199.1(th)15.9(e)-204.3(c)0(h)17.5(i)0(l)18.2(d)-208.2(we)20.5(lf)19.6(ar)14.9(e)-204.3(s)0(y)18.8(s)0(t)21.1(e)0(m)14(.)-205.3(Th)20.1(e)-210.6(a)0(i)19.8(m)-205.4(of)-197.6(th)15.9(e)-210.6(p)13.1(re)21.3(se)16.3(nt)]TJ
T*
[(st)14.7(u)13.1(d)0(y)-233(w)0(a)20.5(s)0(,)-231.2(t)0(h)22.3(e)0(r)14.9(e)0(f)21.2(o)0(r)17.3(e)0(,)-226.1(t)0(o)-230.7(i)0(n)15.9(v)13.1(es)16.3(ti)18.2(g)13.1(a)0(t)19.8(e)-242.2(th)22.3(e)-242.2(u)0(s)18.8(e)-242.2(o)13.1(f)-242.4(th)22.2(es)16.3(e)-242.2(t)0(h)22.3(r)0(e)14.9(e)-235.9(co)17.5(mm)19.2(on)19.9(ly)]TJ
0 -1.2266 TD
[(us)18.8(ed)-260.7(cl)19.8(as)16.3(se)16.3(s)-266.3(o)13.1(f)-274(p)13.1(sy)18.8(ch)17.5(o)13.1(t)0(r)19.6(o)0(p)19.9(i)0(c)-258.4(m)0(e)14(d)13.1(ic)19.8(at)19.8(io)15.9(n)-265.1(i)0(n)-262.3(a)-267.5(re)14.9(p)13.1(r)0(e)21.2(s)0(e)16.3(n)0(t)22.2(a)0(t)13.5(i)15.4(ve)-260.7(No)16.6(rw)20.4(e-)]TJ
0 -1.2203 TD
[(gi)15.9(an)-178.5(co)23.9(ho)19.9(rt)-176.4(of)-178.7(y)13.1(o)0(u)19.9(t)0(h)-180.1(p)13.1(la)19.8(ce)15.1(d)-182.9(i)0(n)-180.1(R)0(C)-179.2(i)15.4(ns)18.7(ti)18.2(tu)22.3(ti)18.2(on)19.9(s,)-180.7(i)15.4(n)0(c)17.5(l)0(u)15.9(d)13.1(in)22.3(g)-189.2(h)13.1(ow)-179.4(th)22.3(is)-181.3(co)23.8(-)]TJ
T*
[(va)17.5(ri)19.6(ed)-260.7(wi)18.9(th)-262.3(re)21.3(as)16.3(o)13.1(n)0(s)-259.4(f)0(o)17.3(r)-267.7(pl)15.9(ac)21.4(em)14(en)23.8(t,)-259.4(ag)17.5(e,)-264.1(an)23.8(d)-271.4(g)0(e)17.5(n)13.1(de)17.5(r.)]TJ
/F3 1 Tf
0 -2.7505 TD
(Methods)Tj
/F11 1 Tf
0 -1.8336 TD
[(Study)-338.6(population)]TJ
/F5 1 Tf
1.1128 -1.8336 TD
-.0196 Tc
[(Participants)-443.9(were)-438.8(all)-446.8(c)3.8(hi)-4.2(ldren)-442.7(a)]TJ
12.6521 0 TD
[(nd)-442.7(adolescents)-443.9(a)-2.6(ged)-442.7(0)6.2(20)-442.7(years)]TJ
8.9663 0 0 8.9663 313.0582 218.8913 Tm
-.0205 Tc
[(pl)-5.1(aced)-323.5(in)-323.5(RC)-321.9(i)-5.1(n)-1(st)-5.1(itut)-5.1(i)1.3(ons)-324.7(under)-319.8(t)-5.1(he)-319.6(N)-4.3(o)-1(rw)-4.3(egi)-5.1(a)2.9(n)-323.5(D)-4.3(irectorat)-5.1(e)-319.6(for)-319.8(C)-5.8(hil-)]TJ
0 -1.2203 TD
-.0199 Tc
[(dren,)-212.5(Y)-3.7(outh)-221.7(a)3.5(nd)-221.7(Fam)-4(ily)-221.7(Affairs,)-218.8(Chil)-4.5(d)-215.4(W)-2.4(el)-4.5(fare)-217.8(Services)-216.6(\(BUFD)-3.8(I)-3(R\))-218(at)]TJ
T*
-.0196 Tc
[(least)-212.8(o)6.2(nce)-211.2(during)-208.8(2016)-208.8(due)-211.2(to)-208.8(one)-211.2(or)-211.4(more)-211.2(of)-211.4(th)6.2(e)-211.2(f)-2.7(ollowing)-208.8(reasons)-210(for)]TJ
T*
-.0185 Tc
[(pla)4.9(cem)3.7(ent:)-369.8(neg)7.3(l)-3.1(e)4.9(c)-1.5(t,)-369.2(em)3.8(erge)4.9(ncy)-365.8(p)]TJ
13.0315 0 TD
[(la)4.9(cem)3.7(ent,)-369.2(se)4.9(rious)]TJ
7.1449 0 TD
-.0197 Tc
[(b)6.1(e)-2.7(havioral)-371(prob-)]TJ
-20.1764 -1.2266 TD
[(lems)-235.3(of)-236.7(high)-240.4(and)-240.4(l)2.2(ow)-237.4(degree,)-237.5(a)-2.6(nd/or)-236.7(su)]TJ
14.8778 0 TD
-.0194 Tc
[(b)6.4(s)-1.1(tance)-236.3(a)-2.4(bu)6.4(se.)-237.3(T).2(his)-235.1(d).1(irectorate)]TJ
-14.8778 -1.2203 TD
-.0191 Tc
[(is)-228.5(respo)6.7(n).4(sible)-223.4(f)-2.2(or)-223.5(all)-231.3(R)2(C)-225.7(i)-3.7(ns)5.5(titutions)-228.5(in)-227.3(Norway)-227.3(ex)6.7(cept)-225(f)-2.2(o)6.7(r)-229.9(those)-229.7(i)2.7(n)-227.3(t)2.7(he)]TJ
T*
-.0208 Tc
[(m)-4.9(unicipality)-317.5(of)-313.8(O)-4.6(s)-2.5(lo,)-314.6(w)1.7(hi)-5.4(ch)-317.5(administ)-5.4(ers)-312.3(i)-5.4(ts)-318.7(ow)-4.6(n)-317.5(i)1(nstit)-5.4(ut)-5.4(ions.)-314.6(C).3(onse-)]TJ
0 -1.2266 TD
-.0195 Tc
[(quently,)-458.7(80%)-457.4(of)-457.9(Norwegian)-461.6(R)1.6(C)-460(i)2.3(nstitu)6.3(t)-4.1(ions)-456.5(were)-457.7(included)-455.3(i)-4.1(n)-455.3(t)2.3(he)]TJ
0 -1.2203 TD
[(pres)5.2(ent)-231.6(s)-1.1(tudy.)-231(Available)-236.3(b).1(ackground)-233.9(da)]TJ
15.1497 0 TD
-.0191 Tc
[(ta)-229.7(on)-233.6(the)-236(p).4(articipants)-228.5(i)-3.7(n)6.7(c)-2.1(luded)]TJ
-15.1497 -1.2203 TD
-.0194 Tc
[(gender,)-281.6(age,)-281.6(and)-278.2(r)-2.5(easons)-279.3(for)-280.8(p).1(lacement)-282.2(in)-278.1(RC)-276.5(in)6.4(stitutions)5.2(.)]TJ
/F11 1 Tf
0 -2.7505 TD
0 Tc
[(Prescription)-338.8(drug)-331.5(data)]TJ
/F5 1 Tf
1.1128 -1.8336 TD
[(For)-391.7(the)-397(RC)-387.8(population,)-398.2(data)-392.6(on)-391(all)-394.7(lled)-392.3(prescriptions)-397.5(during)]TJ
-1.1128 -1.2266 TD
[(2016)-421.7(were)-426.1(available)-422(from)-424.1(the)-416(Norwegian)-424.7(Prescription)-427(Database)]TJ
0 -1.2203 TD
[(\(NorPD\))-186.6(for)-187.1(each)-182.3(individual.)-187.3(The)-184.1(drugs)-184.7(were)-185.8(classied)-188.9(according)-180.2(to)]TJ
/F3 1 Tf
-27.9978 77.2217 TD
(2)Tj
46.1193 0 TD
[(OERBECK)-332.6(ET)-338.7(AL.)]TJ
ET
endstream
endobj
40 0 obj
<>stream
POJBGE+AdvPSMPE7
AdvPSMPE7 |;&љ?D/jWS^pŖ×XD76,օH/ГFF1kWT[qƙœ͖HI3tX\Wbڍ砹p8T?46Qޖܖ׀H3x\<5gЃÈˇC3
endstream
endobj
42 0 obj
<>stream
hTP=0+<`T T:ibH0/\l~zϖ&@t&-A^:ݒ